The effect of the APOE-ε4 allele and ACE-I/D polymorphism on cognition during a two-year follow-up in first-ever stroke patients

Dementia and Geriatric Cognitive Disorders

Volumn 29, Issue 6, 2010, Pages 534-542

  Bour, A M J J ^a   Rasquin, S M C ^d   Baars, L ^b   Van Boxtel, M P J ^b   Visser, P J ^b,c   Limburg, M ^a   Verhey, F R J ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Adelante Zorggroep   (Netherlands)

Author keywords

Angiotensin converting enzyme; Apolipoprotein 4; Cognition; Stroke

Indexed keywords

APOLIPOPROTEIN E4; DIPEPTIDYL CARBOXYPEPTIDASE;

AGED; ALLELE; ARTICLE; COGNITION; COGNITIVE DEFECT; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; PRIORITY JOURNAL; STROKE; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; FOLLOW UP; GENETIC PREDISPOSITION; GENETICS; INDEL MUTATION; MIDDLE AGED; PHYSIOLOGY; RISK FACTOR; STATISTICAL MODEL;

AGED; AGED, 80 AND OVER; APOLIPOPROTEIN E4; CHI-SQUARE DISTRIBUTION; COGNITION; COGNITION DISORDERS; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDEL MUTATION; LINEAR MODELS; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; RISK FACTORS; STROKE;

EID: 77954196002     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314678     Document Type: Article

References (73)

1. Patel M, Coshall C, Rudd AG, Wolfe CD: Natural history of cognitive impairment after stroke and factors associated with its recovery. Clin Rehabil 2003; 17: 158-166.
2. Lesniak M, Bak T, Czepiel W, Seniow J, Czlonkowska A: Frequency and prognostic value of cognitive disorders in stroke patients. Dement Geriatr Cogn Disord 2008; 26: 356-363.
3. Solfrizzi V, Panza F, Colacicco AM, D'Introno A, Capurso C, Torres F, Grigoletto F, Maggi S, Del Parigi A, Reiman EM, Caselli RJ, Scafato E, Farchi G, Capurso A: Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology 2004; 63: 1882-1891.
4. Rockwood K, Howard K, MacKnight C, Darvesh S: Spectrum of disease in vascular cognitive impairment. Neuroepidemiology 1999; 18: 248-254.
5. Gorelick PB, Bowler JV: Advances in vascular cognitive impairment 2007. Stroke 2008; 39: 279-282.
6. Jellinger KA: The pathology of 'vascular dementia': a critical update. J Alzheimers Dis 2008; 14: 107-123.
7. Helzner EP, Luchsinger JA, Scarmeas N, Cosentino S, Brickman AM, Glymour MM, Stern Y: Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol 2009; 66: 343-348.
8. Kalaria RN, Ballard C: Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 1999; 13(suppl 3):S115-S123.
9. O'Brien J, Lilienfeld S: Relevant clinical outcomes in probable vascular dementia and Alzheimer's disease with cerebrovascular disease. J Neurol Sci 2002; 203-204: 41-48. (Pubitemid 35287373)
10. Launer LJ, Petrovitch H, Ross GW, Markesbery W, White LR: AD brain pathology: vascular origins? Results from the HAAS autopsy study. Neurobiol Aging 2008; 29: 1587-1590.
11. Hsiung GY, Sadovnick AD, Feldman H: Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the canadian study of health and aging. CMAJ 2004; 171: 863-867.
12. Knopman DS, Mosley TH, Catellier DJ, Coker LH: Fourteen-year longitudinal study of vascular risk factors, apoe genotype, and cognition: the ARIC MRI study. Alzheimers Dement 2009; 5: 207-214.
13. Kolsch H, Jessen F, Freymann N, Kreis M, Hentschel F, Maier W, Heun R: Ace I/D polymorphism is a risk factor of Alzheimer's disease but not of vascular dementia. Neurosci Lett 2005; 377: 37-39.
14. Morovic S, Jurasic MJ, Martinic Popovic I, Seric V, Lisak M, Demarin V: Vascular characteristics of patients with dementia. J Neurol Sci 2009.
15. Federoff HJ: Alzheimer's disease: reducing the burden with APOE2. Gene Ther 2005; 12: 1019-1029.
16. Bu G: Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 2009; 10: 333-344.
17. Mortimer JA, Snowdon DA, Markesbery WR: The effect of Apoe-epsilon4 on dementia is mediated by Alzheimer neuropathology. Alzheimer Dis Assoc Disord 2009; 23: 152-157.
18. Miners JS, Ashby E, Van Helmond Z, Chalmers KA, Palmer LE, Love S, Kehoe PG: Angiotensin- Converting Enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy. Neuropathol Appl Neurobiol 2008; 34: 181-193.
19. Hassan A, Lansbury A, Catto AJ, Guthrie A, Spencer J, Craven C, Grant PJ, Bamford JM: Angiotensin converting enzyme insertion/ deletion genotype is associated with leukoaraiosis in lacunar syndromes. J Neurol Neurosurg Psychiatry 2002; 72: 343-346.
20. Szolnoki Z, Maasz A, Magyari L, Horvatovich K, Farago B, Somogyvari F, Kondacs A, Szabo M, Fodor L, Bodor A, Hadarits F, Melegh B: Coexistence of angiotensin ii type-1 receptor a1166c and angiotensin-converting enzyme D/D polymorphism suggests susceptibility for small-vessel-associated ischemic stroke. Neuromolecular Med 2006; 8: 353-360.
21. Bartres-Faz D, Junque C, Clemente IC, Lopez- Alomar A, Valveny N, Lopez-Guillen A, Lopez T, Cubells MJ, Moral P: Angiotensin I converting enzyme polymorphism in humans with age-associated memory impairment: relationship with cognitive performance. Neurosci Lett 2000; 290: 177-180.
22. Richard F, Berr C, Amant C, Helbecque N, Amouyel P, Alperovitch A: Effect of the angiotensin I-converting enzyme I/D polymorphism on cognitive decline: the EVA study group. Neurobiol Aging 2000; 21: 75-80.
23. Purandare N, Oude Voshaar RC, Davidson Y, Gibbons L, Hardicre J, Byrne J, McCollum C, Jackson A, Burns A, Mann DM: Deletion/ insertion polymorphism of the angiotensinconverting enzyme gene and white matter hyperintensities in dementia: a pilot study. J Am Geriatr Soc 2006; 54: 1395-1400.
24. Vardy ER, Rice PJ, Bowie PC, Holmes JD, Catto AJ, Hooper NM: Plasma angiotensinconverting enzyme in Alzheimer's disease. J Alzheimers Dis 2009; 16: 609-618.
25. Baum L, Chen X, Cheung WS, Cheung CK, Cheung LW, Chiu KF, Wen HM, Poon P, Woo KS, Ng HK, Wong KS: Polymorphisms and vascular cognitive impairment after ischemic stroke. J Geriatr Psychiatry Neurol 2007; 20: 93-99. (Pubitemid 46878183)
26. Liu H, Liu M, Li W, Wu B, Zhang S, Fang Y, Wang Y: Association of ACE I/D gene polymorphism with vascular dementia: a metaanalysis. J Geriatr Psychiatry Neurol 2008.
27. Arpa A, del Ser T, Goda G, Barba R, Bornstein B: Apolipoprotein E, angiotensin-converting enzyme and alpha-1-antichymotrypsin genotypes are not associated with post-stroke dementia. J Neurol Sci 2003; 210: 77-82.
28. Slooter AJ, Tang MX, van Duijn CM, Stern Y, Ott A, Bell K, Breteler MM, Van Broeckhoven C, Tatemichi TK, Tycko B, Hofman A, Mayeux R: Apolipoprotein E epsilon4 and the risk of dementia with stroke: a population- based investigation. Jama 1997; 277: 818-821.
29. Bowler JV: Vascular cognitive impairment. J Neurol Neurosurg Psychiatry 2005; 76 (suppl 5):v35-v44.
30. Bowler JV: Modern concept of vascular cognitive impairment. Br Med Bull 2007; 83: 291-305.
31. Rasquin SM, Lodder J, Ponds RW, Winkens I, Jolles J, Verhey FR: Cognitive functioning after stroke: a one-year follow-up study. Dement Geriatr Cogn Disord 2004; 18: 138-144.
32. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
33. Van der Elst W, Van Boxtel MP, Van Breukelen GJ, Jolles J: The Stroop Color-Word Test: influence of age, sex, and education; and normative data for a large sample across the adult age range. Assessment 2006; 13: 62-79.
34. Houx PJ, Jolles J, Vreeling FW: Stroop interference: aging effects assessed with the Stroop Color-Word Test. Exp Aging Res 1993; 19:209-224.
35. Brand PA, Jolles J: Learning and retrieval rate of words presented auditorialy and visualy. J Gen Psychol 1985; 112: 201-210.
36. Van der Elst W, van Boxtel MP, van Breukelen GJ, Jolles J: Rey's verbal learning test: normative data for 1,855 healthy participants aged 24-81 years and the influence of age, sex, education, and mode of presentation. J Int Neuropsychol Soc 2005; 11: 290-302.
37. de Koning I, van Kooten F, Dippel DW, van Harskamp F, Grobbee DE, Kluft C, Koudstaal PJ: The CAMCOG: a useful screening instrument for dementia in stroke patients. Stroke 1998; 29: 2080-2086.
38. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Press, 1994.
39. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, et al: Vascular dementia: diagnostic criteria for research studies. Report of the NINDSAIREN international workshop. Neurology 1993; 43: 250-260.
40. Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174.
41. Snijders T, Bosker R: Multilevel Analysis: An Introduction to Basic and Advanced Multilevel Modeling. London, Sage, 1999.
42. Traykov L, Rigaud AS, Caputo L, Couderc R, Coste J, Michot JL, de Rotrou J, Amouyel P, Forette F, Boller F: Apolipoprotein E phenotypes in demented and cognitively impaired patients with and without cerebrovascular disease. Eur J Neurol 1999; 6: 415-421.
43. Frank A, Diez-Tejedor E, Bullido MJ, Valdivieso F, Barreiro P: ApoE genotype in cerebrovascular disease and vascular dementia. J Neurol Sci 2002; 203-204: 173-176.
44. Zhu L, Fratiglioni L, Guo Z, Basun H, Corder EH, Winblad B, Viitanen M: Incidence of dementia in relation to stroke and the apolipoprotein E epsilon4 allele in the very old: findings from a population-based longitudinal study. Stroke 2000; 31: 53-60.
45. Tabet N, Quinn R, Klugman A: Prevalence and cognitive impact of cerebrovascular findings in Alzheimer's disease: a retrospective, naturalistic study. Int J Clin Pract 2009; 63: 338-345.
46. Lewis H, Beher D, Cookson N, Oakley A, Piggott M, Morris CM, Jaros E, Perry R, Ince P, Kenny RA, Ballard CG, Shearman MS, Kalaria RN: Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-beta(42) peptide in vascular dementia. Neuropathol Appl Neurobiol 2006; 32: 103-118.
47. Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, van Duijn CN, Van Broeckhoven C, Grobbee DE: Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam study. Lancet 1997; 349: 151-154. (Pubitemid 27039193)
48. Burlinson S, Burns A, Mann D, Pickering- Brown S, Owen F: Effect of apolipoprotein E status on clinical features of dementia. Int J Geriatr Psychiatry 1998; 13: 177-185.
49. Orsitto G, Seripa D, Panza F, Franceschi M, Cascavilla L, Placentino G, Matera MG, Paris F, Capurso C, Solfrizzi V, Dallapiccola B, Pilotto A: Apolipoprotein E genotypes in hospitalized elderly patients with vascular dementia. Dement Geriatr Cogn Disord 2007; 23: 327-333.
50. Gdovinova Z, Habalova V, Novosadova Z: Polymorphism of apolipoproteine E in relation with Alzheimer and vascular dementia. Cell Mol Neurobiol 2006; 26: 1219-1224.
51. Hardy J: The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 2009; 110: 1129-1134.
52. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ: Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9: 119-128.
53. Baum L, Lam LC, Kwok T, Lee J, Chiu HF, Mok VC, Wong A, Chen X, Cheung WS, Pang CP, Ma SL, Tang NL, Wong KS, Ng HK: Apolipoprotein E epsilon4 allele is associated with vascular dementia. Dement Geriatr Cogn Disord 2006; 22: 301-305.
54. Slooter AJ, Cruts M, Kalmijn S, Hofman A, Breteler MM, Van Broeckhoven C, van Duijn CM: Risk estimates of dementia by apolipoprotein E genotypes from a populationbased incidence study: the Rotterdam study. Arch Neurol 1998; 55: 964-968.
55. Kalmijn S, Feskens EJ, Launer LJ, Kromhout D: Cerebrovascular disease, the apolipoprotein e4 allele, and cognitive decline in a community- based study of elderly men. Stroke 1996; 27: 2230-2235.
56. Liu Y, Laakso MP, Karonen JO, Vanninen RL, Nuutinen J, Soimakallio S, Aronen HJ: Apolipoprotein E polymorphism and acute ischemic stroke: a diffusion- and perfusionweighted magnetic resonance imaging study. J Cereb Blood Flow Metab 2002; 22: 1336-1342.
57. Ballard CG, Morris CM, Rao H, O'Brien JT, Barber R, Stephens S, Rowan E, Gibson A, Kalaria RN, Kenny RA: APOE epsilon4 and cognitive decline in older stroke patients with early cognitive impairment. Neurology 2004; 63: 1399-1402.
58. Wagle J, Farner L, Flekkoy K, Wyller TB, Sandvik L, Eiklid KL, Fure B, Stensrod B, Engedal K: Association between APOE epsilon4 and cognitive impairment after stroke. Dement Geriatr Cogn Disord 2009; 27: 525-533.
59. Engelborghs S, Dermaut B, Goeman J, Saerens J, Marien P, Pickut BA, Van den Broeck M, Serneels S, Cruts M, Van Broeckhoven C, De Deyn PP: Prospective Belgian study of neurodegenerative and vascular dementia: ApoE genotype effects. J Neurol Neurosurg Psychiatry 2003; 74: 1148-1151.
60. Davidson Y, Gibbons L, Pritchard A, Hardicre J, Wren J, Stopford C, Julien C, Thompson J, Payton A, Pickering-Brown SM, Pendleton N, Horan MA, Burns A, Purandare N, Lendon CL, Neary D, Snowden JS, Mann DM: Apolipoprotein E epsilon4 allele frequency and age at onset of Alzheimer's disease. Dement Geriatr Cogn Disord 2007; 23: 60-66.
61. Klages JD, Fisk JD, Rockwood K: APOE genotype, vascular risk factors, memory test performance and the five-year risk of vascular cognitive impairment or Alzheimer's disease. Dement Geriatr Cogn Disord 2005; 20: 292-297.
62. Reitz C, Luchsinger JA, Tang MX, Manly J, Mayeux R: Stroke and memory performance in elderly persons without dementia. Arch Neurol 2006; 63: 571-576.
63. Rowan E, Morris CM, Stephens S, Ballard C, Dickinson H, Rao H, Saxby BK, McLaren AT, Kalaria RN, Kenny RA: Impact of hypertension and apolipoprotein E4 on poststroke cognition in subjects 1 75 years of age. Stroke 2005; 36: 1864-1868.
64. Szolnoki Z, Somogyvari F, Kondacs A, Szabo M, Fodor L, Bene J, Melegh B: Specific APOE genotypes in combination with the ACE D/D or MTHFR 677tt mutation yield an independent genetic risk of leukoaraiosis. Acta Neurol Scand 2004; 109: 222-227.
65. Gustafson DR, Melchior L, Eriksson E, Sundh V, Blennow K, Skoog I: The ACE insertion deletion polymorphism relates to dementia by metabolic phenotype, Apoevarepsilon4, and age of dementia onset. Neurobiol Aging 2010;31:910-916.
66. Kim Y, Kim JH, Nam YJ, Kim YJ, Yu KH, Lee BC, Lee C: Sequence variants of ACE, AGT, AT1R, and PAI-1 as genetic risk factors for vascular dementia. Neurosci Lett 2006; 401: 276-279.
67. Wang HK, Fung HC, Hsu WC, Wu YR, Lin JC, Ro LS, Chang KH, Hwu FJ, Hsu Y, Huang SY, Lee-Chen GJ, Chen CM: Apolipoprotein E, angiotensin-converting enzyme and kallikrein gene polymorphisms and the risk of Alzheimer's disease and vascular dementia. J Neural Transm 2006; 113: 1499-1509.
68. Jokinen H, Kalska H, Mantyla R, Pohjasvaara T, Ylikoski R, Hietanen M, Salonen O, Kaste M, Erkinjuntti T: Cognitive profile of subcortical ischaemic vascular disease. J Neurol Neurosurg Psychiatry 2006; 77: 28-33.
69. Jokinen H, Kalska H, Mantyla R, Ylikoski R, Hietanen M, Pohjasvaara T, Kaste M, Erkinjuntti T: White matter hyperintensities as a predictor of neuropsychological deficits post-stroke. J Neurol Neurosurg Psychiatry 2005; 76: 1229-1233.
70. Loewenstein DA, Acevedo A, Agron J, Issacson R, Strauman S, Crocco E, Barker WW, Duara R: Cognitive profiles in Alzheimer's disease and in mild cognitive impairment of different etiologies. Dement Geriatr Cogn Disord 2006; 21: 309-315.
71. Busse A, Angermeyer MC, Riedel-Heller SG: Progression of mild cognitive impairment to dementia: a challenge to current thinking. Br J Psychiatry 2006; 189: 399-404.
72. Rasquin SM, Verhey FR, Lousberg R, Lodder J: Cognitive performance after first ever stroke related to progression of vascular brain damage: a 2-year follow-up CT scan study. J Neurol Neurosurg Psychiatry 2005; 76: 1075-1079.
73. Sachdev PS, Chen X, Brodaty H, Thompson C, Altendorf A, Wen W: The determinants and longitudinal course of post-stroke mild cognitive impairment. J Int Neuropsychol Soc 2009; 15: 915-923.